Latest Applied genetics Stories
AMSTERDAM, July 7, 2011 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera(R)with the European Medicines Agency.
A Washington State University student's undergraduate research is challenging a widely held assumption on the best way to analyze old DNA in anthropological and forensic investigations.
--Children's Hospital of Philadelphia Study Advances New Strategy for Gene Therapy-- PHILADELPHIA, June 26, 2011 /PRNewswire-USNewswire/ -- Using an innovative gene therapy technique called genome editing that hones in on the precise location of mutated DNA, scientists have treated the blood clotting disorder hemophilia in mice.
AMSTERDAM, June 24, 2011 /PRNewswire/ -- - Dossier Re-Examination Process Initiated Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has received an opinion on its Marketing Authorisation Application (MAA) for Glybera(R) (alipogene tiparvovec) as a potential therapy for Lipoprotein Lipase Deficiency ("LPLD").
DNA relationship testing, primarily for paternity cases, is on the rise in the United States increasing more than 400 percent in the past two decades, according to the latest AABB (American Association of Blood Banks) Annual Report Summary for DNA Relationship Testing.
Using forensic genetics techniques, the UA's Conservation Genetics Lab is working to protect wild animals and catch the criminals in cases of wildlife crime.
FORT LEE, N.J., June 8, 2011 /PRNewswire/ -- Neurologix, Inc.
An investigation into direct-to-consumer (DTC) genetic tests found flawed and inaccurate results, with each one giving different results, and in some cases arriving at medical predictions that were no more accurate than flipping a coin.
FORT LEE, N.J., May 26, 2011 /PRNewswire/ -- Neurologix, Inc.
AMSTERDAM, May 23, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today the results from studies exploring the role of adeno-associated viral (AAV) vectors for the efficient delivery of short and micro RNA to inhibit disease by RNA interference.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.